Home > Resources > Whitepapers > Review of Mental Health Clinical Pharmacists in Veterans Health Administration Facilities

Review of Mental Health Clinical Pharmacists in Veterans Health Administration Facilities

June 27, 2019

The VA Office of Inspector General (OIG) conducted a healthcare inspection to assess Veterans Health Administration (VHA) facilities utilization of clinical pharmacists who work under a scope of practice in a mental health outpatient care setting.1 On August 1, 2018, the OIG published a report that identified risks to patients if mental health care provided by clinical pharmacists is not properly monitored.2 In that report, the OIG made recommendations pertaining to clinical oversight of clinical pharmacists and formal collaborating agreements between clinical pharmacists and independent providers at one medical facility. The seriousness of the risks identified in the prior report led the OIG to initiate a broader review of clinical pharmacists practice in mental health outpatient care settings.

Spotlight

Eye Health America

Eye Health America partners with eye care practices and ambulatory surgery centers to provide superior clinical care. Our member practices offer full-service eye care from routine eye exams, contact lenses and glasses to medical ophthalmology and surgery including cataract, cornea, retina, glaucoma, pediatrics and oculoplastics. We support practice groups and ASCs as they grow locations and service offerings, enabling them to focus on delivering the highest quality outcomes and meeting a rapidly growing need for eye care.

OTHER WHITEPAPERS

2023 Telehealth White Paper Publication

whitePaper | July 20, 2023

Healthcare delivery through telehealth allows a provider to consult with patients remotely through electronic and telecommunication technologies. Prior to the COVID-19 Public Health Emergency (PHE), telehealth services were, generally, only used and paid for in limited circumstances.

Three Challenges Facing Study Start Up and the Low-Code Automation Solution

whitePaper | November 24, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

whitePaper | December 20, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

Beyond the Bottom Line

whitePaper | May 4, 2023

Presented in the paper is a comprehensive overview of the nuances of revenue cycle management (RCM) and the intricacies of handling it internally in a hard-pushed healthcare setting.

Porter Research for Healthcare and Life Sciences

whitePaper | May 16, 2023

The healthcare and life sciences communities have been undergoing a massive digital transformation since the COVID-19 pandemic. Everything from healthcare consumer expectations to government regulations are driving providers, payers, and pharmaceutical organizations to move aggressively toward digital interactions and transactions

More Whitepapers

Review of Mental Health Clinical Pharmacists in Veterans Health Administration Facilities